Shubham Pant, MD, Highlights the Potential of ELI-002 2P to Treat MRD in KRAS-Mutant Solid Malignancies


Shubham Pant, MD, spoke to the potential of ELI-002 2P as a treatment for minimal residual disease positivity in patients with KRAS-mutant solid tumors.

In an interview with CancerNetwork® during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, Shubham Pant, MD, associate professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, spotlighted the ongoing phase 1 AMPLIFY-201 trial (NCT04853017) assessing ELI-002 2P in patients with KRAS-mutant with solid tumors that were positive for minimal residual disease by circulating tumor DNA (ctDNA).


The abstract I presented this morning was [about a] trial in progress. It’s very important for [oncology professionals] to know about which trials are ongoing that could have a patient care impact. We had a very interesting trial of patients with minimal residual disease in solid tumors. Now that concept has made it in the mainstream more in leukemia and [other] hematologic malignancies, but it’s coming to the forefront in patients with solid tumor malignancies. What we are doing in this trial is [examining] patients with resected colon cancer even with resected liver metastases, pancreatic cancer, ovarian cancer, non–small cell lung cancer, or biliary tract cancers who have no evidence of disease. When we do a scan, there’s no evidence of disease; but when we take their blood sample for ctDNA, they’re positive. Then, they can get an experimental vaccine targeted against a KRAS mutation.

KRAS has long been called undruggable, but there are a lot of different small molecules and vaccine therapies that are trying to change the tide. I’m really excited about this trial [and there is] a lot of enthusiasm from other investigators. [It] is ongoing at our institution and multiple other institutions.


Pant S, Furqan M, Muhsin R, et al. First-in-human phase 1 trial of ELI-002 immunotherapy as treatment for subjects with Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma and other solid tumors. J Clin Oncol. 2022;40(suppl 16):TPS2701. doi:10.1200/JCO.2022.40.16_suppl.TPS2701

Related Videos
Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.
Lenvatinib in combination with pembrolizumab appears to raise no new safety signals in patients with advanced clear cell renal cell carcinoma after 4 years of follow-up in the phase 3 CLEAR study.
According to Thomas E. Hutson, DO, PharmD, FACP, 4-year follow-up data from the phase 3 CLEAR study confirm the maintained benefits of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Rana R. McKay, MD discusses presentations of interest that were presented at the 2023 Kidney Cancer Research Summit, including a discussion on how PET imaging may identify which patients with renal cell carcinoma may respond to immunotherapy.
A better understanding of tumor biology may be necessary for identifying novel non-immunotherapy–based therapeutic strategies for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Probiotics and other agents targeting fatty acid oxidation are also under evaluation as treatment options for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Other angiogenic agents are also under investigation in renal cell carcinoma, according to Rana McKay, MD, who indicates it will be interesting to see how they compare with belzutifan.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.